Bicycle Therapeutics (NASDAQ:BCYC) Stock: Insider Kevin Lee Sells 6,167 Shares

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) CEO Kevin Lee sold 6,167 shares of Bicycle Therapeutics stock in a transaction dated Friday, October 2nd. The stock was sold at an average price of $3.47, for a total value of $21,399.49. Following the sale, the chief executive officer directly owned 597,504 shares of the company’s stock, valued at $2,073,338.88. This trade represents a 1.02% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kevin Lee also recently made the following trade(s):

• On Monday, October 5th, Kevin Lee sold 1,638 shares of Bicycle Therapeutics stock. The shares were sold at an average price of $3.57, for a total value of $5,847.66.

Bicycle Therapeutics Price Performance

NASDAQ:BCYC traded down $0.22 during midday trading on Tuesday, hitting $3.79. The company’s stock had a trading volume of 620,678 shares, compared to its average volume of 422,826. Bicycle Therapeutics PLC Sponsored ADR has a fifty-two week low of $3.33 and a fifty-two week high of $9.16. The firm has a market cap of $265.27 million, a P/E ratio of -1.39 and a beta of 1.68. The firm’s 50 day moving average is $3.96 and its 200-day moving average is $4.31.

Bicycle Therapeutics (NASDAQ:BCYC) last announced its quarterly earnings data on Thursday, July 30th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.14). The business had revenue of $0.63 million for the quarter, compared to analyst estimates of $4.22 million. Bicycle Therapeutics had a negative net margin of 311.11% and a negative return on equity of 33.22%. As a group, analysts forecast that Bicycle Therapeutics PLC Sponsored ADR will post -2.26 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have commented on BCYC shares. Wall Street Zen raised shares of Bicycle Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, August 15th. Needham & Company LLC reduced their price objective on Bicycle Therapeutics from $15.00 to $14.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Bicycle Therapeutics in a report on Wednesday, July 8th. Five equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $13.86.

Institutional Trading of Bicycle Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. GAMMA Investing LLC boosted its stake in shares of Bicycle Therapeutics by 512.9% during the 2nd quarter. GAMMA Investing LLC now owns 7,704 shares of the company’s stock worth $33,000 after acquiring an additional 6,447 shares in the last quarter. Portland Investment Counsel Inc. purchased a new position in shares of Bicycle Therapeutics in the 2nd quarter valued at about $64,000. Royal Bank of Canada increased its stake in shares of Bicycle Therapeutics by 35.5% in the 1st quarter. Royal Bank of Canada now owns 14,470 shares of the company’s stock valued at $67,000 after purchasing an additional 3,788 shares in the last quarter. R Squared Ltd acquired a new position in Bicycle Therapeutics in the 1st quarter worth about $98,000. Finally, FNY Investment Advisers LLC raised its holdings in Bicycle Therapeutics by 247.4% in the 2nd quarter. FNY Investment Advisers LLC now owns 26,250 shares of the company’s stock worth $111,000 after purchasing an additional 18,693 shares during the period. Institutional investors and hedge funds own 86.15% of the company’s stock.

About Bicycle Therapeutics

Bicycle Therapeutics plc (NASDAQ:BCYC) is a clinical-stage biotechnology company developing medicines based on its proprietary Bicycle molecule platform. The platform uses short, chemically constrained peptides designed to bind selectively to biological targets, with the goal of combining the tissue penetration and target specificity of small molecules with some of the binding characteristics of larger biologic medicines.

The company is focused primarily on oncology and is developing Bicycle toxin conjugates, immune-cell engaging molecules and other targeted therapeutics.